Mikołaj Słabicki, Ph.D., is a Principal Investigator at the MGH Krantz Family Center for Cancer Research, an Assistant Professor of Medicine at Harvard Medical School, and an Affiliate Faculty Member at the Broad Institute of MIT and Harvard.

 

Mikołaj established his laboratory in the summer of 2024. His research focuses on expanding the druggable proteome by leveraging functional genomics, high-throughput screening, chemical biology, cell biology, and biochemical techniques. His team aims to discover and characterize new molecular glue degraders and explore novel mechanisms of targeted protein degradation.

​

Dr. Mikołaj Słabicki earned his Master’s degree from the Technical University of Łódź and completed his Ph.D. under the guidance of Dr. Frank Buchholz at the Max Planck Institute of Molecular Cell Biology and Genetics in Dresden, Germany. He pursued postdoctoral research at NCT/DKFZ in Heidelberg, followed by a Marie Skłodowska-Curie Fellowship in Dr. Stefan Fröhling’s lab at the German Cancer Research Center in Heidelberg and Dr. Benjamin Ebert’s lab at the Dana-Farber Cancer Institute. Mikołaj subsequently became a Group Leader in the Ebert Lab within the Cancer Program at the Broad Institute of MIT and Harvard. Additionally, he co-founded and organizes the Dana-Farber Targeted Protein Degradation Webinar series.